Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Epilepsy, Tonic-Clonic Clear all
Enrolling by invitation Phase 3 Interventional

An Open-label Study of XEN1101 in Epilepsy

NCT05718817
View directory record Official record
Conditions
Focal Epilepsy, Tonic-Clonic Seizures
Interventions
XEN1101
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
54
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

NCT05064878
View directory record Official record
Conditions
CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
Interventions
Fenfluramine, Placebo
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
1 Year to 35 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

NCT02823145
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride)
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Novel Helmet Design in Patients With Seizures

NCT03443388
View directory record Official record
Conditions
Drug Resistant Epilepsy, Drop Seizures, Generalized Tonic Clonic Seizure, Complex Partial Seizure, Fall Due to Seizure
Interventions
Hövding inflatable helmet
Device
Lead sponsor
Michael A. Gelfand, MD, PhD
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 22, 2026, 4:37 AM EDT
Completed No phase listed Observational

Seizure Detection and Warning System in Epilepsy Patients

NCT02555410
View directory record Official record
Conditions
Epilepsy, Generalized Tonic-Clonic Seizures
Interventions
Brain Sentinel Seizure Detection and Warning System
Device
Lead sponsor
Brain Sentinel
Other
Eligibility
2 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Results available

IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures

NCT00510783
View directory record Official record
Conditions
Tonic-clonic Seizure
Interventions
Keppra, Fosphenytoin, Dilantin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

NCT02926898
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride), Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures

NCT00104416
View directory record Official record
Conditions
Epilepsy, Tonic-Clonic
Interventions
lamotrigine (LAMICTAL) extended-release, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
64
States / cities
Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Sep 22, 2026, 4:37 AM EDT
Terminated No phase listed Observational

Evaluation and Treatment of Patients With Epilepsy

NCT00013845
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
2 Years and older
Enrollment
1,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 22, 2026, 4:37 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142
View directory record Official record
Conditions
Primary Generalized Tonic-Clonic Seizures
Interventions
XEN1101, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
59
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Terminated Phase 2Phase 3 Interventional

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures

NCT06425159
View directory record Official record
Conditions
Generalized Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

NCT03678753
View directory record Official record
Conditions
Primary Generalized Epilepsy
Interventions
Cenobamate, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
12 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
43
States / cities
Phoenix, Arizona • Tuscon, Arizona • Fresno, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Not applicable Interventional

Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study

NCT03446664
View directory record Official record
Conditions
Epilepsies, Partial, Epilepsy, Tonic-Clonic
Interventions
Microburst Stimulation
Device
Lead sponsor
LivaNova
Industry
Eligibility
12 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Birmingham, Alabama • Denver, Colorado • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional

Cenobamate Open-Label Extension Study for YKP3089C025

NCT03961568
View directory record Official record
Conditions
Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
Interventions
Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
16
States / cities
La Jolla, California • Miami, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome

NCT03299842
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride)
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
San Francisco, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 22, 2026, 4:37 AM EDT
Not listed Not applicable Interventional

Assessment of the Emfit Mattress Sensor for Detection and Alarm of Night-time Generalized Tonic-clonic Seizures.

NCT02661919
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Emfit mattress sensor
Device
Lead sponsor
Emfit, Corp.
Industry
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

NCT02408549
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide Tablet, Lacosamide Oral Solution
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
4 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
16
States / cities
Little Rock, Arkansas • Santa Monica, California • Colorado Springs, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Not applicable Interventional

RNS System NAUTILUS Study

NCT05147571
View directory record Official record
Conditions
Epilepsy, Idiopathic Generalized Epilepsy, Generalized Tonic Clonic Seizure
Interventions
Responsive stimulation, Sham stimulation
Device
Lead sponsor
NeuroPace
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Enrolling by invitation Phase 3 Interventional

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

NCT07287163
View directory record Official record
Conditions
Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Interventions
vormatrogine
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 85 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Miami, Florida • Miami Lakes, Florida • Naples, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Completed No phase listed Observational

Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System in Epilepsy Patients

NCT02371200
View directory record Official record
Conditions
Epilepsy, Generalized Tonic-Clonic Seizures
Interventions
Brain Sentinel Seizure Detection and Warning System
Device
Lead sponsor
Brain Sentinel
Other
Eligibility
2 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Charleston, South Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

NCT01118949
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Alabaster, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

NCT01465997
View directory record Official record
Conditions
Epilepsy, Monotherapy
Interventions
Lacosamide, Carbamazepine-Controlled Release (CBZ-CR)
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
Not listed
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Alabaster, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

NCT02849626
View directory record Official record
Conditions
Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
29
States / cities
Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 22, 2026, 4:37 AM EDT
Terminated Phase 4 Interventional

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

NCT05684978
View directory record Official record
Conditions
Refractory Status Epilepticus
Interventions
Perampanel
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 22, 2026, 4:37 AM EDT